WilmerHale Represented the Underwriters in $178M Public Offering of Disc Medicine

WilmerHale Represented the Underwriters in $178M Public Offering of Disc Medicine

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the underwritten public offering of 4,944,000 shares of common stock by Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. Disc received approximately $178.0 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. The offering priced on June 14, 2017 and closed on June 17, 2024.

The WilmerHale team representing the underwriters included Lisa Firenze, Ryan Brewer, Alex Bloom and Michelle Sidle with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar on intellectual property matters.

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel